Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return

Why Arrowhead Pharmaceuticals Is Drawing Investor Attention Now Arrowhead Pharmaceuticals (ARWR) is back on many watchlists after a sharp total return over the past 3 months and the past year. This ...

Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million

This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its ...
American Association of Individual Investors

Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or BeOne Medicines AG Stock?

Learn more about whether Arrowhead Pharmaceuticals, Inc. or BeOne Medicines AG is a better investment based on AAII's A+ ...
American Association of Individual Investors

Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or Gilead Sciences, Inc. Stock?

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Seeking Alpha

Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade)

Arrowhead Pharmaceuticals has surged over 240% in six months, driven by major partnerships and its RNAi drug pipeline. Recent catalysts include a $200M Novartis deal, $300M from Sarepta, and the first ...